Program
rosuvastatin
Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.
Drug pageRosuvastatin: every studyMany companies study it; this page follows only the 138 they lead. All 405 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 705 open or running | phase 4since Oct 7, 2005 | Sep 16, 2005 | Jan 25, 2027phase 1 · NCT07534592 |
| Yuhanits history only | 100 open or running | phase 4since Jul 12, 2017 | Jan 5, 2012 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 80 open or running | phase 2since Nov 27, 2016 | Jan 24, 2014 | none ahead |
| Organonits history only | 60 open or running | phase 4since Mar 31, 2008 | Aug 25, 2004 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 1since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Merckits history only | 40 open or running | phase 3since Oct 10, 2025 | Jun 17, 2015 | none ahead |
| Hanlim Pharm.its history only | 30 open or running | phase 3since Jun 17, 2018 | Jun 17, 2018 | none ahead |
| IlDong Pharmaceuticalits history only | 30 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 30 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| Lotus Pharmaceuticalits history only | 30 open or running | phase 3since May 13, 2015 | Mar 4, 2014 | none ahead |
| Celltrionits history only | 20 open or running | phase 3since Apr 27, 2026 | Jul 30, 2021 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Nov 7, 2019 | Mar 14, 2014 | none ahead |
| Daiichi Sankyoits history only | 20 open or running | phase 1since Sep 11, 2025 | Sep 11, 2025 | none ahead |
| Hanmi Pharmaceuticalits history only | 20 open or running | phase 1since Mar 9, 2014 | Mar 9, 2014 | none ahead |
| kobe-universityits history only | 20 open or running | phase 4since Jun 15, 2017 | Jun 15, 2017 | none ahead |
| LG Chemits history only | 20 open or running | phase 3since Aug 5, 2013 | Aug 5, 2013 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| d16-pharma-biotec-ltdits history only | 10 open or running | phase 4since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Dong-A STits history only | 10 open or running | phase 4since Oct 29, 2014 | Oct 29, 2014 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| NVP Healthcareits history only | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| pin-siang-medical-biotechnology-co-ltdits history only | 10 open or running | no phasesince Nov 6, 2013 | Nov 6, 2013 | none ahead |
| verisfield-uk-ltd-greek-branchits history only | 10 open or running | phase 1since May 9, 2016 | May 9, 2016 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Pfizer, Regeneron Pharmaceuticals, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly, Linical Korea and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Oct 29, 2014.
- Dec 2, 2024Phase 3 study in DyslipidemiasAstraZeneca · NCT06834932 · 432 enrolled · China, Hong Kong
- Dec 16, 2024Phase 1 study in DyslipidemiasAstraZeneca · NCT06742853 · 81 enrolled · United States, United Kingdom
- May 23, 2025Hansoh Pharmaceutical Group’s first study: phase 1 study in DyslipidemiasNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07001787 · 88 planned
- Jul 17, 2025Phase 1 study in Healthy ParticipantsAstraZeneca · NCT07088913 · 20 enrolled · United States
- Sep 11, 2025Daiichi Sankyo’s first studies: 2 phase 1 studies in Healthy SubjectsNew to Daiichi SankyoDaiichi Sankyo · NCT07182383, NCT07201545
- Oct 10, 2025Phase 3 study in HyperlipidemiasMerck · NCT07216482 · 996 enrolled · United States, Argentina, Australia and more
- Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
- Dec 10, 2025Phase 1 study in HealthyMerck · NCT07300280 · 60 enrolled · United States
- Dec 19, 2025Phase 1 study in HyperlipidemiasAstraZeneca · NCT07316608 · 44 enrolled · United States
- Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592 · 48 enrolled · United States
- Apr 27, 2026Phase 3 study in HypertensionPhase 3 reachedCelltrion · NCT07564726 · 163 enrolled · South Korea
- May 26, 20262 phase 3 studies in HypercholesterolemiaAstraZeneca · NCT07619131, NCT07619118
- Nov 5, 2026Phase 3 study in HypercholesterolemiaAstraZeneca · NCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
- Nov 10, 2026Primary completion moved from 2026-10-01 to 2027-01-25Date moved laterphase 1 · +4 months · NCT07534592
Ahead
- Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592
- Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasAstraZeneca · NCT06834932
- May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaAstraZeneca · NCT07619118
- Jul 30, 2027Primary completion: phase 3 study in HypercholesterolemiaAstraZeneca · NCT07619131
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 138 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more | 3 | Not yet recruiting | AstraZeneca | Oct 11, 2027 | 204 |
| NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more | 3 | Recruiting | AstraZeneca | Jul 30, 2027 | 600 |
| NCT07619118Hypercholesterolemia · United States, Australia, Canada and more | 3 | Recruiting | AstraZeneca | May 28, 2027 | 200 |
| NCT07564726Hypertension · South Korea | 3 | Completed | Celltrion | Feb 13, 2024 | 163 |
| NCT07534592Diabetes Mellitus, Type 2 · United States | 1 | Active, not recruiting | AstraZeneca | Jan 25, 2027 | 48 |
| NCT07316608Hyperlipidemias · United States | 1 | Completed | AstraZeneca | Jun 5, 2026 | 44 |
| NCT07300280Healthy · United States | 1 | Completed | Merck | Oct 14, 2026 | 60 |
| NCT07222098Healthy · United States | 1 | Completed | Merck | Dec 14, 2025 | 16 |
| NCT07216482Hyperlipidemias · United States, Argentina, Australia and more | 3 | Completed | Merck | Aug 3, 2026 | 996 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Nov 24, 2025 | 58 |
| NCT07088913Healthy Participants · United States | 1 | Completed | AstraZeneca | Feb 20, 2026 | 20 |
| NCT07001787Dyslipidemias | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Feb 2026 | 88 |
| NCT06742853Dyslipidemias · United States, United Kingdom | 1 | Completed | AstraZeneca | Oct 29, 2025 | 81 |
| NCT06834932Dyslipidemias · China, Hong Kong | 3 | Active, not recruiting | AstraZeneca | Feb 22, 2027 | 432 |
| NCT06646354Hypertension · Korea, Republic of | 3 | By invitation | hyundai-pharm | May 19, 2025 | 125 |
| NCT06554821Healthy Participants · Germany | 1 | Completed | AstraZeneca | Oct 8, 2024 | 28 |
| NCT06475872Primary Hypercholesterolemia · Korea, Republic of | 1 | Completed | Hanlim Pharm. | Dec 7, 2023 | 36 |
| NCT06160414Healthy · United Kingdom | 1 | Completed | AstraZeneca | Feb 5, 2024 | 20 |
| NCT06112678Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Feb 19, 2024 | 63 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | AstraZeneca | Jun 24, 2023 | 6 |
| NCT05749861Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jun 7, 2023 | 65 |
| NCT05549401Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Nov 30, 2022 | 32 |
| NCT05384262Dyslipidemias · United States, United Kingdom | 1 | Completed | AstraZeneca | Jun 14, 2024 | 183 |
| NCT05192356Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 8, 2022 | 63 |
| NCT05002244Health, Subjective · Korea, Republic of | 1 | Completed | Celltrion | Aug 29, 2021 | 37 |
| NCT04883658Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 20, 2021 | 62 |
| NCT04659070Hypertension · Korea, Republic of | 3 | UNKNOWN | Hanlim Pharm. | May 19, 2022 | 156 |
| NCT04428086Solid Tumor, Adult · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 22, 2021 | 19 |
| NCT04258865Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 26, 2020 | 30 |
| NCT04161001Hypertension · Korea, Republic of | 3 | UNKNOWN | Daewoong Pharmaceutical | Nov 20, 2021 | 237 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT04056169Acute Coronary Syndrome · Korea, Republic of | 4 | Completed | Yuhan | Jul 23, 2019 | 50 |
| NCT03872232Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Aug 12, 2020 | 180 |
| NCT03847506Hypertension · Korea, Republic of | 4 | Completed | HK inno.N | Dec 2, 2020 | 127 |
| NCT03657758Coronary Artery Disease · Japan | 4 | UNKNOWN | kobe-university | Aug 31, 2020 | 75 |
| NCT03571087Primary Hypercholesterolemia | 3 | Completed | Hanlim Pharm. | Aug 2015 | 374 |
| NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 16, 2017 | 134 |
| NCT03550859Renal Insufficiency, Chronic · Korea, Republic of | 4 | UNKNOWN | Yuhan | Dec 2021 | 374 |
| NCT03217409Diabetes Mellitus · Korea, Republic of | 4 | Completed | Yuhan | Apr 3, 2019 | 85 |
| NCT03192579Coronary Artery Disease Progression | 4 | Completed | kobe-university | Jun 2, 2017 | 50 |
| NCT03019549Healthy · United States | 1 | Completed | AstraZeneca | May 22, 2017 | 42 |
| NCT02977065Dyslipidemias · Australia | 2 | Completed | Chong Kun Dang Pharmaceutical | Dec 30, 2017 | 62 |
| NCT02963116High Risk Coronary Artery Disease · United Kingdom | 1 | Completed | AstraZeneca | Mar 1, 2017 | 12 |
| NCT03210532Hypertension · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Sep 2017 | 129 |
| NCT02933658Hypertension | 1 | Completed | Daewon Pharmaceutical | Nov 2015 | 71 |
| NCT02951962Hypertension · Korea, Republic of | 1 | Completed | Yuhan | Sep 2016 | 60 |
| NCT02859129Hypertriglyceridemia · United States | 1 | Completed | AstraZeneca | Nov 2013 | 114 |
| NCT02827903Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Jeil Pharmaceutical | Nov 21, 2017 | 237 |
| NCT02767310Healthy · India | 1 | Completed | verisfield-uk-ltd-greek-branch | Jun 2016 | 49 |
| NCT02748057Hypercholesterolemia | 3 | Completed | Organon | Dec 11, 2017 | 135 |
| NCT02741245Hypercholesterolemia | 3 | Completed | Organon | Jan 18, 2017 | 321 |
| NCT02707224Healthy | 1 | Completed | Lotus Pharmaceutical | Jun 2015 | 40 |
| NCT02546323Atherosclerosis · China | 3 | Completed | AstraZeneca | Jan 29, 2019 | 543 |
| NCT02477514Skin Diseases, Bacterial | 1 | Completed | Merck | Aug 2015 | 18 |
| NCT02445352Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | Lotus Pharmaceutical | Jan 2015 | 379 |
| NCT02434497Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more | 3 | Completed | AstraZeneca | Nov 17, 2016 | 9 |
| NCT02387619Hypertension · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 41 |
| NCT02289430Healthy | 1 | Completed | NVP Healthcare | Feb 2015 | 59 |
| NCT02280590Hyperlipidemias · Korea, Republic of | 4 | Completed | Dong-A ST | Jun 2015 | 223 |
How it is read
Names in the registry
- “Rosuvastatin”, 105 entries
- “rosuvastatin”, 10 entries
- “CKD-828, D097, D337”, 6 entries
- “Rosuvastatin 20mg”, 6 entries
- “Ezetimibe/Rosuvastatin”, 4 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 43 studies
- Hypertension, 23 studies
- Dyslipidemias, 9 studies
- Hyperlipidemias, 6 studies
- Coronary Artery Disease, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.